Optic Nerve Atrophy Stem Cell Medical Reports
Summaries of published research on stem cell therapy for optic nerve atrophy, each linking to the original study.
-
Neural Regeneration Research · 2025-06-19
Cell-Based Therapies for Traumatic Optic Neuropathy: Recent Advances, Challenges, and Perspectives
Yuanhui Wang, Moxin Chen, Zhimin Tang and Ping Gu.
-
BMC Ophthalmology · 2024-07-29
Evaluating the Impact of Mesenchymal Stem Cell Therapy on Visual Acuity and Retinal Nerve Fiber Layer Thickness in Optic Neuropathy Patients: A Comprehensive Systematic Review and Meta-Analysis
Samira Chaibakhsh, Fatemeh Azimi, Alireza Shoae-Hassani, Parvin Niknam, Ali Ghamari, Samaneh Dehghan and Naveed Nilforushan.
-
Stem Cell Research & Therapy · 2023-09-21
Intravitreal Allogeneic Mesenchymal Stem Cells: A Non-Randomized Phase II Clinical Trial for Acute Non-Arteritic Optic Neuropathy
Jose C. Pastor, Salvador Pastor-Idoate, Marina López-Paniagua, Marta Para, Francisco Blazquez, Esther Murgui, Verónica García and Rosa M. Coco-Martín.
-
Molecular Neurodegeneration · 2023-09-21
Retinal Ganglion Cell Repopulation for Vision Restoration in Optic Neuropathy: A Roadmap From the RReSTORe Consortium
Jonathan R. Soucy, Erika A. Aguzzi, Julie Cho, Michael James Gilhooley, Casey Keuthan, Ziming Luo, Aboozar Monavarfeshani, Meher A. Saleem, Xue-Wei Wang, Juilette Wohlschlegel, The RReSTORe Consortium, Petr Baranov, Adriana Di Polo, Brad Fortune, Kimberly K. Gokoffski, Jeffrey L. Goldberg, William Guido, Alex L. Kolodkin, Carol A. Mason, Yvonne Ou, Thomas A. Reh, Ahmara G. Ross, Brian C. Samuels, Derek Welsbie, Donald J. Zack and Thomas V. Johnson.
-
Frontiers in Cell and Developmental Biology · 2026-03-04
The Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells-Derived Exosomes for Retinal and Optic Nerve Diseases
Mingzhe Shi, Shounan Qi, Feifan Qi and Chenguang Wang.
-
2021-06-11
Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges
Rosa M. Coco-Martin, Salvador Pastor-Idoate, Jose Carlos Pastor, Yolanda Diebold, and Laura García-Posadas
-
2015-05-14
Stem cell treatment of degenerative Eye Disease
Ben Mead, Martin Berry, Ann Logan, Robert A.H. Scott, Wendy Leadbeater, Ben A. Scheven
-
2019-02-13
Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa
Parker E. Ludwig, S. Caleb Freeman, Adam C. Janot.
-
Stem Cell Investigation · 2019-12-05
Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy
Jeffrey N. Weiss, Steven Levy.
-
2016-11-26
Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials
Sonia Labrador-Velandia, María Luz Alonso-Alonso, Sara Alvarez-Sanchez, Jorge González-Zamora, Irene Carretero-Barrio, José Carlos Pastor, Iván Fernandez-Bueno, and Girish Kumar Srivastava
-
2011-09-02
Age-Related Macular Degeneration: Current Treatment and Future Options
Tanya Moutray, Usha Chakravarthy
-
2002-11-01
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes
Neil M Bressler, Jennifer Arnold, Mustapha Benchaboune, Mark S Blumenkranz, Gary E Fish, Evangelos S Gragoudas, Hilel Lewis, Ursula Schmidt-Erfurth, Jason S Slakter, Susan B Bressler, Kelly Manos, Yong Hao, Laurie Hayes, John Koester, Al Reaves, H Andrew
-
2012-02-28
Anti-VEGF Treatment Strategies for Wet AMD
Jaclyn L. Kovach, Stephen G. Schwartz, Harry W. Flynn, Jr, Ingrid U. Scott
-
2003-05-01
Visual function in patients with optic nerve pallor (optic atrophy)
Christine A. DeWitt, Lenworth N. Johnson, Dana B. Schoenleber, Dean P. Hainsworth, and Richard W. Madsen
-
2020-07-20
The Diagnosis and Treatment of Age-Related Macular Degeneration
Andreas Stahl.
-
2022-08-08
Optic Atrophy
Syed Shoeb Ahmad; Venkata M. Kanukollu.
Speak with a patient representative
No obligation. We’ll review your situation and respond within 48 hours.
- Response within 48 hours from a patient representative.
- Confidential — your information stays with us.
- No cost, no obligation. We review your case and respond.
Answering patient inquiries since 2005. A medical evaluation follows once we have your completed medical questionnaire.
